Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,617.10 -329.83 (-0.85%) Hang Seng
19,195.60 -25.02 (-0.13%) FTSE 100
8,358.40 -58.05 (-0.69%) Bitcoin USD
69,929.91 -647.44 (-0.92%) CMC Crypto 200
1,506.01 -20.41 (-1.34%)
Stoke Therapeutics, Inc. (STOK)
| Previous close | 15.35 |
| Open | 15.34 |
| Bid | 15.70 x 200 |
| Ask | 15.92 x 200 |
| Day's range | 14.80 - 15.95 |
| 52-week range | 3.35 - 16.44 |
| Volume | |
| Avg. volume | 1,396,898 |
| Market cap | 824.537M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
- Business Wire
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BEDFORD, Mass., May 06, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause
- Business Wire
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BEDFORD, Mass., April 29, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his p
